Leadership Team

Board of Directors

Recent Resources

Press

January 11, 2021

Canadian Program to Deploy Cancer Testing During COVID-19 Reaches Key Milestones, Adds New Partners

With a strategic investment from Canada’s Digital Technology Supercluster, Project ACTT is speeding up cancer testing for targeted treatment selection during the pandemic through a minimally invasive circulating tumor (ctDNA) DNA test, which is available as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer.

Press

December 3, 2020

Canexia Health Co-Founder David Hunstman’s exclusive interview with OncLive

Canexia Health's Co-Founder and Chief Medical Officer David Hunstman was recently interviewed by OncLive as part of their OncLive On Air Podcast. In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Press

January 17, 2020

Contextual Genomics and EORLA Partner for Early Access to ctDNA Cancer Testing

Contextual Genomics and Eastern Ontario Regional Laboratory Association, a nonprofit organization offering high quality, patient focused, hospital-based lab services in Eastern Ontario, announced that they have partnered to bring Contextual Genomics’ ctDNA cancer genomic testing to EORLA’s Champlain Local Health Integration Network of Eastern Ontario, Canada.

Press

January 13, 2020

Contextual Genomics and Lab Genomics Partner for Liquid Biopsy Cancer Testing

Contextual Genomics and Lab Genomics, a personalized medicine company providing state of the art molecular genetic testing in Southern California, announced that they have signed an agreement enabling Lab Genomics to offer Contextual Genomics’ quality assured Next Generation Sequencing based ctDNA cancer genomic testing to patients in Southern California and other parts of the United States.

Sorry, nothing at the moment.

Sorry, nothing at the moment.

Solutions that drive precision oncology

Our precision cancer assays digitize biologic samples and make high-quality cancer genomic information accessible and affordable. Discover Find It,  Follow  It, and the Fusions panel.

Explore Our Solutions